Does Acute Oxytocin Administration Enhance Social Cognition in Individuals With Schizophrenia?
Overview
- Phase
- Not Applicable
- Intervention
- Inactive placebo nasal spray
- Conditions
- Schizophrenia
- Sponsor
- VA Greater Los Angeles Healthcare System
- Enrollment
- 24
- Locations
- 1
- Primary Endpoint
- Social Cognition Composite Measure
- Status
- Completed
- Last Updated
- 12 years ago
Overview
Brief Summary
Individuals with schizophrenia have been found to have deficits in social cognition, which is defined as the functions that are engaged during social interactions. Social cognition has been found to be critical in predicting multiple aspects of community functioning. There are no currently available medications that have been consistently found to improve social cognition in individuals with schizophrenia. Oxytocin functions as a neurotransmitter that is thought to be involved in multiple aspects of social behavior and related emotions. In this study, we test the hypothesis that acute administration of intranasal oxytocin will improve social cognition in individuals with schizophrenia.
Detailed Description
Schizophrenia is characterized by the presence of positive symptoms (delusions, hallucinations, disorganization of thought process and behavior) as well as negative symptoms (blunted affect, alogia, and avolition), neurocognitive deficits, and impaired social cognition. While positive symptoms can often respond well to antipsychotic medications, the latter symptoms are more difficult to treat. In this study, we will focus on social cognition, which is defined as the functions that are engaged during social interactions. Social cognition has been categorized into four main domains: theory of mind, social perception, attributional bias, and emotional processing. Social cognition in patients with schizophrenia has been found to be critical in predicting multiple aspects of community functioning. There are currently two broad approaches to improve social cognition in patients with schizophrenia: pharmacological and psychosocial interventions. While psychosocial interventions (training exercises to target improvement in domains of social cognition) have shown some benefit, their resultant improvements have been limited in their distribution across multiple domains as well as their generalization to improved functioning in the community. Pharmacological trials have yielded mixed results, and there are not any currently available medications that have been consistently found to improve social cognition in patients with schizophrenia2. One potential future therapeutic target for enhancing social cognition is the oxytocin system. Oxytocin is a nine-amino acid peptide that, in addition to its role in the periphery for regulating lactation and uterine contractions, functions centrally as a neurotransmitter which is involved in multiple aspects of social behavior and related emotions. Specifically, it has been found to modulate emotion recognition, trust, eye contact, empathic accuracy, as well as envy and gloating. Given oxytocin's role in social functioning, in conjunction with the deficits in social functioning found frequently in individuals with schizophrenia, there have been several studies over the past three decades examining the oxytocin system in humans with schizophrenia and in rodent experimental models. It has been found that individuals with schizophrenia do not show the same level of increase in oxytocin as normal controls in response to trust-related interpersonal interactions, and low plasma oxytocin predicted negative symptoms of schizophrenia. Additionally, it has also been found that plasma oxytocin levels predicted the ability of patients with schizophrenia to identify facial expressions. Finally, it has been found recently that sustained regular administration of intranasal oxytocin significantly reduced both positive and negative symptoms of schizophrenia. Thus, there is significant evidence supporting further research studying the effect of oxytocin on social cognition. It is not yet known if exogenous administration of oxytocin will have acute effects on neuropsychological measures of social cognition in individuals with schizophrenia, and this is the focus of this proposed pilot study. The overall hypothesis guiding this study is that acute oxytocin administration will improve social cognition (as assessed by a composite score comprising two measures of "low level" social cognitive processes and two measures of "high level" social cognitive processes) in individuals with schizophrenia. Our primary goals are to assess the feasibility of this experimental paradigm and to generate pilot data and obtain estimates of effect sizes which can be used in planning future larger studies.
Investigators
Michael C. Davis, M.D., Ph.D.
Fellow / Physician
VA Greater Los Angeles Healthcare System
Eligibility Criteria
Inclusion Criteria
- •Veteran being treated in the Veterans Administration Healthcare System
- •Meet DSM-IV-TR criteria for Schizophrenia
- •At least 6 months since any hospitalization or substantial increase in level of care for an acute exacerbation of psychotic symptoms
- •At least 1 month since meeting the criteria for having a major depressive episode
- •At least 6 months since any behaviors suggesting any potential danger to self or others
- •Adherence to the regular administration of an antipsychotic medication (e.g., risperidone, olanzapine, quetiapine, ziprasidone, aripiprazole, paliperidone, iloperidone, asenapine, fluphenazine, haloperidol, loxapine, molindone, perphenazine, thiothixene, chlorpromazine, clozapine)
- •Dose of antipsychotic medication not varying by more than 25% over the 3 months prior to study participation
- •No acute medical problems
- •Chronic medical conditions (e.g., hypertension, diabetes, dyslipidemia) consistently treated and stable for at least 3 months prior to study participation
- •Ability to provide signed informed consent and to cooperate with study procedures
Exclusion Criteria
- •Documented history of mental retardation or severe learning disability
- •History of treatment with electroconvulsive therapy within 6 months prior to study participation
- •History of neurological or neuropsychiatric condition (e.g., stroke, severe traumatic brain injury, epilepsy, etc.)
- •Documented history of persistent substance abuse or dependence within 6 months prior to study participation
- •History of hyponatremia within the past 6 months
- •Allergic rhinitis or other inflammation of the nasal mucosa
Arms & Interventions
Inactive nasal spray
A placebo nasal spray will be prepared to be otherwise identical to the active treatment nasal spray except lacking oxytocin. The ingredients in the inactive nasal spray are mannitol, glycerin, and preserved water.
Intervention: Inactive placebo nasal spray
Intranasal Oxytocin
Oxytocin nasal spray (40 units/ml) will be administered in a single intranasal dose of 40 IU. Its formula is: oxytocin 1 unit/mg mannitol trituration 0.2Gm + glycerin USP 0.1ml + preserved water 5ml.
Intervention: Oxytocin
Outcomes
Primary Outcomes
Social Cognition Composite Measure
Time Frame: Visit 2 (baseline), Visit 3 (1 week following, post-treatment)
Our primary outcome measure will be a composite score created by calculating the mean of the four main social cognition measures assessed in this study (two "high-level" measures and two "low-level" measures). Because these measures are not on the same scale, we will first z-score (center and scale) each of the four measures at each time point using the baseline mean and standard deviation of the whole sample and then calculate the mean of the z-scores to create the composite social cognition score.
Secondary Outcomes
- Theory of Mind Assessment (High Level Social Cognition)(Visit 2 (baseline), Visit 3 (1 week following, post-treatment))
- Empathy(Visit 2 (baseline), Visit 3 (1 week following, post-treatment))
- Social Perception Assessment (Low Level Social Cognition)(Visit 2 (baseline), Visit 3 (1 week following, post-treatment))
- Facial Affect Recognition (Low Level Social Cognition)(Visit 2 (baseline), Visit 3 (1 week following, post-treatment))
- Positive and Negative Syndrome Scale (PANSS) for Schizophrenia Total Score(Visit 2 (baseline), Visit 3 (1 week following, post-treatment))